How to Choose a Hemp or Cannabis Manufacturing Partner in India: A Buyer’s Due-Diligence Checklist


By Delta Botanicals & Research | 2 November 2026
A manufacturer sends you a polished catalogue, a GMP certificate and an attractive quotation. The sample looks good. The minimum order seems manageable.
Before you pay the advance, ask one question:
What evidence connects this factory to the exact product I intend to sell?
The answer should connect the formulation, the manufacturing site, the relevant permissions and the standard your finished batch must meet.
Choosing a hemp or cannabis manufacturing partner in India means checking three things together: permission to undertake the proposed work, capability to deliver it consistently and commercial terms your business can sustain.
This guide turns that assessment into a practical buying process. Use it before shortlisting a factory, commissioning a pilot or committing to commercial production.
This is a buyer-side due-diligence framework, not a product approval or legal opinion. Applicable requirements depend on the formulation, material, activity, state and market. The commercial safeguards below are recommended checks, not a claim that every item is a universal statutory requirement.
The five checks to complete before paying a production advance
Identify the product pathway. Hemp-seed food, Ayurvedic medicine, cosmetic and pharmaceutical development require different assessments.
Match permissions to the actual work. Check the legal entity, manufacturing premises, product scope and relevant material-handling activities.
Agree the specification. Define what an acceptable finished batch must contain, how it will be tested and who can release it.
Compare complete costs. Include testing, packaging, development, freight and the cash tied up in the minimum order.
Put responsibility in writing. Resolve rejected batches, changes, delays, formula rights and complaints before placing the order.
Assess mandatory requirements first. Compare price only among manufacturers that meet them for the stage you are approving.
1. Start with the product, then identify the manufacturing pathway
“Hemp manufacturer” is a search term. It does not tell you whether a company can lawfully make your particular product.
Two bottles can look almost identical while containing very different materials and requiring different regulatory treatment.
Proposed product | What to establish before selecting a manufacturer |
Hemp-seed food, seed oil or seed flour | Whether the ingredient and finished food meet the applicable FSSAI standards, and whether the operator’s permissions cover the proposed activity and premises. |
Ayurvedic formulation containing Vijaya/Bhanga | The formulation’s regulatory basis, manufacturing and product permissions, applicable cannabis-related clearance, lawful input sourcing and relevant quality requirements. |
Topical or personal-care product | Whether it is properly classified as a cosmetic or a drug, considering composition, intended use and claims. A topical format alone does not settle classification. |
Cannabinoid-containing oral oil, capsule or gummy | The exact ingredient, source, intended use and lawful product route. Do not assume that the format or the term “wellness” makes it a food or supplement. |
Pharmaceutical or phytopharmaceutical candidate | The development stage, relevant drug permissions, evidence requirements and capability to manufacture to the required quality standard. |
Bulk cannabis-derived extract or ingredient | What material the facility may receive, possess, process and supply, and for which authorised onward use. Finished-product permissions do not automatically answer these questions. |
FSSAI has standardised hemp seeds and specified seed products. Its November 2022 clarification confirms their sale subject to licensing and the prescribed standards. This should not be read as blanket permission for every cannabinoid-containing food. Check the actual formulation against the relevant food standards.
For Ayurvedic cannabis products, also examine the Ministry of Ayush’s 7 August 2024 order. It directs central review of existing licences for specified cannabis-containing ASU drugs and central clearance before the grant of relevant manufacturing licences. Ask for documentary evidence of the position applicable to the proposed product, including subsequent directions. A general statement that the factory is “AYUSH licensed” is insufficient.
The NDPS Act distinguishes resin, flowering or fruiting tops, and seeds and leaves when not accompanied by the tops. That distinction does not establish unrestricted permission for every extraction process or finished product. Map the actual material and activities, including relevant state requirements.
Three products, three different manufacturing assessments
Consider three hypothetical briefs:
A bottled hemp-seed oil sold as food. The buyer needs evidence appropriate to the food pathway, including the actual source oil, relevant composition and quality tests, food-contact packaging and support for the shelf life. A cannabinoid-extract brochure does little to answer those questions.
An Ayurvedic formulation containing Vijaya. The buyer needs to connect the proposed formula and ingredients to the relevant drug permissions and cannabis-related clearance position. Familiarity with Ayurvedic oils alone does not demonstrate permission for this formulation.
A bulk cannabis-derived extract for another manufacturer. The buyer needs to establish the starting material, permitted processing and supply activities, extract specification and authorised onward use. A licence for an unrelated finished product does not close those gaps.
These are assessment examples, not determinations that the proposed products are approved. The right factory is the one whose evidence matches the actual brief.
For the wider development sequence, read our guide to launching a hemp or cannabinoid product in India.
2. Send every manufacturer the same product brief
A meaningful comparison starts with comparable requests.
Prepare a one-page brief covering:
Product category, intended user, sales market and proposed claims.
Dosage form or food format, ingredients and target composition.
Pack size, packaging requirements and shelf-life target.
White-label, modified-formula or custom-development requirement.
Initial order quantity and realistic reorder forecast.
Target manufacturing budget and intended launch window.
Required evidence, testing and documents.
Questions that still need regulatory or technical resolution.
State which points are confirmed and which remain provisional. Do not present an unresolved classification as an approved pathway.
Ask each manufacturer to identify what it can supply, what requires development, what it outsources and what it cannot yet confirm.
3. Request documents that answer specific questions
Collecting certificates is easy. Establishing what they prove takes more work.
Request the following evidence as applicable to your product and stage. Confidential records can be reviewed under an NDA, through controlled access or by an agreed independent reviewer.
Document or evidence | What it helps establish | What it does not establish |
Legal-entity details, invoice particulars and bank confirmation | Who you are contracting with and paying | Manufacturing permission or technical competence |
Manufacturing licence and relevant annexures or endorsements | Authorised entity, premises and scope, subject to conditions and current status | Permission for every product, ingredient or activity |
Product-specific permissions and applicable clearance correspondence | The documented position for the proposed formulation | Approval of future changes or unrelated marketing claims |
Relevant GMP evidence | Compliance status within the stated scheme and scope | That every batch passes, or that all cannabis activities are authorised |
Input-source, purchase and movement records, where applicable | Material origin and the documented supply chain | Finished-product quality |
Agreed formula and finished-product specification | What is to be manufactured and the acceptance criteria | That a particular batch meets them |
Batch-specific certificate of analysis, or COA | Results for identified samples and reported parameters | Every possible hazard, lawful sourcing or the identity of an unlinked shipment |
Test methods and laboratory scope | Suitability and recognised competence for specified testing | Competence for tests or materials outside that scope |
Stability and packaging-compatibility evidence | Support for the proposed shelf life and pack under studied conditions | Equivalent performance after an unassessed formula or pack change |
Batch records, deviations and corrective-action examples | How production and quality problems are recorded and controlled | That the system is consistently followed without further review |
Quality and manufacturing agreements | Allocation of responsibilities, deliverables and remedies | Removal of either party’s statutory obligations |
Check names, addresses, scope, conditions and current status. Where available, verify through the issuing authority or official register rather than relying solely on a sales representative’s PDF.
Check current status even where a licence has no fixed expiry date. For GMP evidence, establish the issuer, scheme, scope and applicable validity conditions.
For ASU products, the Ministry has described manufacturing and medicine licensing, applicable GMP and product-quality requirements in its official regulatory explanation. Apply the current rules to the actual product; do not treat a certificate as a substitute for that exercise.
4. How to assess a hemp or cannabis manufacturing partner in India
1. Regulatory scope: can this facility undertake this work?
Match the proposed formulation, dosage form, premises and material-handling steps to the permissions provided. Identify the actual factory behind the quotation and any subcontractors.
Clarify who holds each relevant permission and which obligations fall on your own business.
Hold if: the manufacturer cannot connect the proposed work to a documented regulatory basis.
2. Technical capability: can it reproduce the product at scale?
Ask for experience with comparable formats and processes. Review the proposed equipment, batch size, mixing or filling controls and packaging capability.
For an oral oil, ask how the manufacturer will demonstrate uniform composition and consistent delivery from the chosen dispenser. For a powder, ask how blend uniformity and moisture are controlled. Evidence should relate to your proposed process and batch scale.
Evidence to seek: a technical review of your brief and an agreed pilot plan with measurable acceptance criteria.
3. Sourcing: can the ingredients be obtained lawfully and consistently?
Identify the source material, processor and critical suppliers. Check batch traceability and how the manufacturer qualifies substitutes.
A sample made with an ingredient that cannot be secured for repeat production is a development risk.
Evidence to seek: source records, specifications and realistic lead times. See our hemp and cannabinoid ingredient-sourcing guide.
4. Testing: will the results answer the right questions?
Agree a product-specific testing plan. Depending on the pathway and risks, it may include identity, cannabinoid profile, microbiology, heavy metals, pesticides, residual solvents, oxidation or other relevant parameters.
Record the method, units, acceptance limit, sampling responsibility and test frequency. For a “not detected” result, establish the detection or quantification limit and whether it can demonstrate compliance.
NABL explains that accreditation covers specified tests and capabilities. Check the relevant matrix, method and scope, plus any regulatory recognition required for the intended purpose.
Hold if: the manufacturer offers only an unrelated ingredient COA as evidence for your finished product.
A useful response identifies the finished-product specification, sampling plan, laboratory, methods and release decision. A generic “third-party tested” statement leaves each of those questions open.
5. Quality systems: what happens when something goes wrong?
Ask how incoming materials are quarantined and released, equipment is cleaned, batches are documented and deviations are investigated.
Request a redacted example of a quality failure and its corrective action. A useful answer explains what happened, who investigated and how recurrence was addressed.
Evidence to seek: functioning procedures, named quality responsibility and records demonstrating their use.
6. Capacity: is there space for your order?
Separate installed capacity from capacity available to your project.
Ask which line will run the product, the practical batch range, existing commitments and the plan for a reorder. Identify outsourced processing, testing and packing.
Hold if: the quoted timeline depends on an unidentified facility or unconfirmed production slot.
7. MOQ: can your business absorb the commitment?
Distinguish the manufacturing minimum from minimums for each ingredient, bottle, label, carton, flavour or SKU.
Ask who owns unused packaging and raw materials, how they are stored and what happens if they expire.
Decision test: model slow sales as well as the preferred forecast. A lower unit price is useful only if the resulting order is affordable and saleable.
8. Pricing: what will accepted, saleable stock actually cost?
Request an itemised quote covering development, ingredients, production, testing, packaging, setup charges, freight and applicable taxes.
Separate one-time costs from repeat-batch costs. Record quote validity, yield assumptions, permitted overrun or underrun and the basis for future increases.
Compare: the cost of accepted units delivered to the agreed location, using the same specification and assumptions.
9. Timelines: what must happen before dispatch?
Break the schedule into document review, development, permissions where needed, material procurement, packaging approval, production, testing, release and delivery.
Define what starts each timeline and which dependencies are outside the manufacturer’s control.
Hold if: a launch date is promised before essential inputs, approvals or testing requirements are understood.
10. Formula ownership: what are you paying to own or use?
Separate the manufacturer’s existing formulation and know-how from work developed specifically for your project.
Clarify ownership or usage rights for the formula, modifications, methods, stability data, artwork and technical dossier. Define exclusivity by product, territory, channel and duration where relevant.
Do not assume: paying a development fee automatically gives you ownership or transfer rights.
11. Change control: who can alter the product?
Agree which changes require advance notice, your written approval, testing or regulatory action.
Cover ingredient suppliers, source material, process, manufacturing site, specification, test method, packaging and subcontractors.
Hold if: the manufacturer reserves unrestricted substitution rights while promising consistent product quality.
12. Complaints and recalls: can an affected batch be traced?
Identify who receives complaints, assesses safety concerns, investigates, informs the relevant parties and coordinates withdrawal or recall.
Pick a finished-batch number and ask the team to trace it back to the ingredient lots, production and packing records, and release results, then forward to dispatch records.
Quantities should reconcile, including documented losses, retained samples and stock still on hand. Agree who maintains the onward customer records needed for a recall.
A convincing demonstration produces linked records and explains discrepancies. A statement that “everything is in our software” does not demonstrate traceability.
Evidence to seek: named contacts, response deadlines and clear responsibilities. Cost disputes must not delay necessary protective action.
5. Use a comparison worksheet that keeps missing evidence visible
Use one worksheet per manufacturer, then compare candidates side by side.
For each area, record the document reference and date, the unresolved question, the person responsible for resolving it and the deadline. “They said yes on the call” is an open item until adequately supported.
Assessment area | Evidence received: reference/date | Unresolved question, owner and deadline | Proceed / Hold / Reject |
Regulatory scope | To complete | To complete | To decide |
Technical capability | To complete | To complete | To decide |
Sourcing | To complete | To complete | To decide |
Testing | To complete | To complete | To decide |
Quality systems | To complete | To complete | To decide |
Capacity | To complete | To complete | To decide |
MOQ | To complete | To complete | To decide |
Pricing | To complete | To complete | To decide |
Timelines | To complete | To complete | To decide |
Formula ownership | To complete | To complete | To decide |
Change control | To complete | To complete | To decide |
Complaints and recalls | To complete | To complete | To decide |
Completed example: a testing gap
Illustrative entry for a hypothetical Ayurvedic oral-oil project; not a finding about any manufacturer.
Worksheet field | Completed entry |
Area and stage | Testing; approval for commercial production |
Evidence received | Extract COA EX-041 and quotation Q-017, received 2 November 2026 |
Finding | The COA identifies the input extract. No agreed finished-oil specification, sampling plan or release-testing commitment has been supplied. |
Action and owner | Manufacturer’s quality lead to supply the proposed specification, methods, laboratory details and test-cost allocation; buyer’s technical reviewer to assess them. |
Deadline | Before authorisation of commercial production |
Decision | Hold. Reassess after the required evidence is reviewed and acceptance criteria are agreed. |
This is the level of detail that makes a worksheet useful: a specific gap, an accountable person and an explicit condition for reconsideration.
Set mandatory requirements before comparing proposals. Include applicable permissions, acceptable sourcing, essential testing and quality controls, traceability and any non-negotiable commercial requirements.
Use these decision rules:
Proceed: adequate evidence supports the defined next stage, and its mandatory requirements are met.
Hold: a potentially resolvable evidence gap or unmet condition blocks that stage.
Reject: a confirmed incompatibility, falsified evidence or refusal to meet an essential requirement makes the candidate unsuitable.
A hold is not an allegation of wrongdoing. It means the buyer does not yet have enough evidence to proceed.
Record the stage explicitly. Approval to undertake lawful feasibility work is not approval for commercial manufacture; approval of a manufacturer is not acceptance of every future batch.
Worked example: separate unit cost from cash commitment

Hypothetical figures only, not manufacturer quotations or market benchmarks. Assume both candidates have passed the mandatory checks, quote against the same product and packaging specification, and deliver the full ordered quantity as accepted, saleable units.
Cost item | Manufacturer A | Manufacturer B |
Quoted unit price, including agreed packaging | ₹180 | ₹215 |
Minimum order quantity (MOQ) | 5,000 units | 2,000 units |
Base batch cost | ₹9,00,000 | ₹4,30,000 |
One-time development/setup | ₹30,000 | ₹20,000 |
Agreed batch testing | ₹20,000 | Included |
Freight to the agreed destination | ₹15,000 | ₹10,000 |
First-order delivered cost before tax | ₹9,65,000 | ₹4,60,000 |
Delivered cost per accepted unit before tax | ₹193 | ₹230 |
Manufacturer A remains cheaper per unit. Manufacturer B requires ₹5,05,000 less for the first order before tax and leaves the buyer with fewer units to sell. Neither fact alone determines the better choice.
Compare those commitments with realistic sales, available cash and remaining shelf life. Then add applicable taxes and any separately identified charges to calculate the actual cash requirement. Payment milestones determine when that cash is due. The table excludes launch marketing, warehousing, channel costs and other operating expenses, so it is not a complete launch budget.
For repeat orders, recalculate after removing genuinely non-recurring charges. Do not assume development or setup costs disappear without written confirmation.
If either candidate has an unresolved mandatory permission or essential quality gap, put that candidate on hold before using this commercial comparison.
6. Resolve these contract questions before committing
The manufacturing agreement and quality agreement should work together. Have the terms reviewed for your product and transaction.
Contract issue | Question to resolve in writing |
Scope and subcontracting | Which legal entity and site will perform each activity? Can work move elsewhere without approval? |
Formula and data rights | What do we own, what do we license, and which records and data can we access or transfer? |
Acceptance and rejected batches | Which specification governs acceptance? How are defects notified, investigated and resolved? Who pays for replacement, refund, return or lawful disposal? |
Disputed test results | Which sampling procedure, retained samples, methods and independent laboratory will be used? Who pays while the dispute is resolved? |
Payment milestones | What deliverable triggers each payment? What happens to advances if an agreed prerequisite fails? |
Delays and cancellation | What are the dependencies, notification duties, remedies and cancellation rights? How are unused materials treated? |
Changes and price revisions | Which changes need written approval, additional evidence or regulatory action? When can prices change? |
Complaints and recalls | Who acts, communicates, supplies records and bears costs according to responsibility? |
Changing manufacturers | What documents, know-how, tooling and materials are transferable, at what cost and within what period? |
Termination and continuity | What happens to open orders, retained samples, records, confidentiality and ongoing safety obligations? |
Consider milestone payments tied to documented outputs rather than dates alone. For example, development acceptance, agreed procurement, conforming production and release documentation may each form a milestone, depending on the project.
A contractual right to transfer a formula does not itself authorise production at another factory. The receiving site must meet the relevant permissions and technical requirements.
7. Verify the factory and the pilot before the commercial batch
A site visit should answer questions that a catalogue cannot.
Follow the proposed product through material receipt, storage, production, packing, testing and release. Check whether the premises match the documents. Speak with the people responsible for production and quality, not only sales.
Where an in-person visit is impractical, start with a structured remote review and decide whether the remaining risks require an on-site audit.
For the pilot, agree:
The formula, process, batch size and intended manufacturing site.
The tests and acceptance criteria.
Packaging performance and delivery accuracy, where relevant.
The records you will receive and who reviews them.
What must be corrected before commercial production.
Before accepting a commercial batch, match the delivered lot to its release documents, verify the agreed remaining shelf life and inspect the shipment. Investigate discrepancies before distributing stock.
Frequently asked questions
Is a GMP certificate enough to select a cannabis manufacturer?
No. It is one part of the evidence. You still need to establish the relevant permissions, product and site scope, input sourcing, technical capability, testing and contractual responsibilities.
Can an FSSAI-licensed manufacturer automatically make CBD products?
No. An FSSAI licence does not establish that every proposed cannabinoid ingredient or formulation is permitted. Assess the exact product against its applicable regulatory framework.
Should I choose white label or a custom formulation?
Choose based on your product goals, budget, differentiation and required rights. An existing formulation may reduce development work, but you still need to assess its permissions, evidence and suitability. A custom-development fee does not automatically confer ownership.
Does a successful sample prove commercial readiness?
No. A sample demonstrates limited performance under the conditions in which it was made. Commercial readiness also depends on repeatability, suitable production controls, testing, packaging, documentation and the applicable permissions.
Can I change manufacturers later?
Potentially, but the ease of transfer depends on your contract, access to technical information, receiving-site capability and regulatory requirements. Negotiate those arrangements before paying for development.
Assess your shortlist before committing to production
Already speaking with manufacturers?
Share your product brief and shortlist with Delta Botanicals & Research. Include the proposed format, ingredients, claims, target market, initial quantity, budget and the quotations or documents already received.
An agreed assessment can give you:
A comparison of shortlisted manufacturers against your product brief.
An evidence-gap register showing what is missing and who needs to answer.
Recommended proceed, hold or reject decisions for the stage being assessed, with reasons and next steps.
The purpose is to help you decide which conversations deserve to progress, which conditions must be resolved and what to settle before committing money.
Please begin with a non-confidential summary. Confidential formulations and supplier records can follow under an agreed confidentiality arrangement. Assessment scope, fees, site visits and testing coordination are agreed separately; an assessment does not replace statutory permission or laboratory testing.
Official references
FSSAI: Food Products Standards and Food Additives compendium, including Chapter 2.16.
FSSAI: clarification on hemp seeds and seed products, November 2022.
Ministry of Ayush: order concerning specified cannabis-containing ASU drugs, 7 August 2024.
Government of India: ASU drug licensing, quality and GMP explanation.
India Code: Narcotic Drugs and Psychotropic Substances Act, 1985.
CDSCO: new-drug and phytopharmaceutical regulatory resources.
NABL: accreditation and scope FAQs.
For detailed formulation and manufacturing-structure considerations, read our Ayurvedic cannabis product-development guide.
_edited.png)



Comments